An en banc federal appeals court gave a terse answer to pleas by executives of one of the pharmaceutical industry’s biggest corporations to rescue their careers: No.

The full U.S. Court of Appeals for the D.C. Circuit refused on November 29 to hear an appeal by Michael Friedman, Paul Goldenheim and Howard Udell of Purdue Frederick Co., who were convicted of misdemeanor misbranding tied to the promotion of thepainkiller Oxycontin as less addictive than other medication.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]